Suenaga Mitsukuni, Akiyoshi Takashi, Shinozaki Eiji, Fujimoto Yoshiya, Matsusaka Satoshi, Konishi Tsuyoshi, Nagayama Satoshi, Fukunaga Yosuke, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Ueno Masashi, Yamaguchi Toshiharu
Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Anticancer Res. 2018 Mar;38(3):1741-1747. doi: 10.21873/anticanres.12410.
BACKGROUND/AIM: Past studies have suggested that adjuvant capecitabine and oxaliplatin (CAPOX) provides decreased tumor relapse and longer survival in patients with curatively resected colon cancer. We report the first evidence of the feasibility of adjuvant CAPOX in Japanese patients with early colon cancer.
Eligible patients had histologically-confirmed stage II/III colon cancer and received curative resection. The primary endpoint was completion rate of treatment after 8 cycles of adjuvant CAPOX.
Thirty-six patients were enrolled in this study. The completion rate of CAPOX and oxaliplatin were 77.8% and 61.1%, respectively. The incidence of grade ≥3 adverse events was neutropenia (n=6), thrombocytopenia (n=3), nausea (n=5), hand-foot syndrome (n=1) and peripheral sensory neuropathy (n=1). Three-year disease-free survival for stage II patients and stage III patients were 100% and 79.3%, respectively.
Adjuvant CAPOX can be safely administered to Japanese patients with stage II/III colon cancer.
背景/目的：既往研究表明，辅助性卡培他滨联合奥沙利铂（CAPOX方案）可降低根治性切除结肠癌患者的肿瘤复发率并延长生存期。我们报告了辅助性CAPOX方案在日本早期结肠癌患者中可行性的首个证据。
符合条件的患者经组织学确诊为II/III期结肠癌并接受了根治性切除。主要终点是辅助性CAPOX方案8个周期后的治疗完成率。
本研究纳入了36例患者。CAPOX方案和奥沙利铂的治疗完成率分别为77.8%和61.1%。≥3级不良事件的发生率为中性粒细胞减少（n = 6）、血小板减少（n = 3）、恶心（n = 5）、手足综合征（n = 1）和周围感觉神经病变（n = 1）。II期患者和III期患者的3年无病生存率分别为100%和79.3%。
辅助性CAPOX方案可安全应用于日本II/III期结肠癌患者。
